External Contributer Articles of Labiotech.eu

About

Many authors are contributing to Labiotech.eu. If you want to join them, feel free to reach out to us with your article ideas.

Articles by External Contributor

News and Trends 20 Oct 2016

Planning a Clinical Trial? Here’s why Data Management matters

Data from therapy development, especially those involving cells, can quickly mushroom into an unmanageable pile in the lab — what happens when you move to the clinic? We sat down with Venn Life Sciences to discuss effective strategies in data management that might benefit companies looking to bring a therapy like Tregs to market. Cell […]

October 20, 2016 - 4 minutesmins - By External Contributor

News and Trends 10 Oct 2016

The CRISPR Revolution is here, but how can we make it Useful?

By this point, you can’t have escaped hearing about CRISPR. First discovered in the 1980’s, the repeated sequences and their function in bacterial defense systems remained a mystery until almost 10 years ago, when it was hailed as the biggest scientific discovery of the century. Since then, scientists have leveraged the adaptable, heritable mechanism to develop the most powerful gene-editing technology […]

October 10, 2016 - 6 minutesmins - By External Contributor

News and Trends 3 Oct 2016

Ask the Biotech Recruiter: The Top 10 Pitfalls in International Recruitments

Are you recruiting talent for the top levels of your company? Ask the biotech recruiter! It doesn’t matter if you’re a small-time biotech or a big-time pharma – it’s a tough process. Pact & Partners, a leading international headhunting firm, has your back with this advice on the most common mistakes and how to avoid […]

October 3, 2016 - 9 minutesmins - By External Contributor

News and Trends 29 Jun 2016

How to Survive the Valley of Death as a Biotech Startup?

Over the past decade there has been an unprecedented restructuring of R&D in pharma whereas building a successful biotech company is still as challenging. How can these two elements help each other? This is a contributing post from Peter Machin, former SVP Drug Discovery at GSK. Big Pharma has significantly contracted its in-house […]

June 29, 2016 - 5 minutesmins - By External Contributor

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us